Abstract
The previous study has researched that combining YKL-5-124, CDK7 specific target drug with anti-PD-1 treatment had a survival advantage in various Small Cell Lung Cancer models. However, the molecular mechanism that YKL-5-124 triggers inflammatory response remains unknown. This study investigates the effects of CDK7 inhibition by YKL-5-124 on two DNA damage pathways (ATM and ATR) of SCLC in vitro. The result of this study will reveal the effects of CDK7 inhibition by YKL-5-124 on the molecular mechanisms of SCLC and potentially promote the development of new anticancer treatment strategies based on immunity manipulation.